Sign In
Buy CORT
$114.49
-3.83 (-3.24%)
At Close: Jul 31, 2026
Avidity Partners Management LP Has $1.21 Million Position in Corcept Therapeutics Incorporated $CORT
03:49am, Saturday, 01'st Aug 2026
Avidity Partners Management LP lifted its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 36.4% in the undefined quarter, according to the company in its most recent disclosure with the S
Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It
11:34am, Friday, 31'st Jul 2026
Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already reflected in a premium valuation. LIFYORLI generated $47.6M in its first full quarter, with management
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
01:06pm, Thursday, 30'th Jul 2026
Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.
Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript
07:33pm, Wednesday, 29'th Jul 2026
Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
07:26pm, Wednesday, 29'th Jul 2026
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year
Corcept Therapeutics Q2 Earnings Call Highlights
06:04pm, Wednesday, 29'th Jul 2026
Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing's syndrome franchise increased and its newly laun
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
04:05pm, Wednesday, 29'th Jul 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
10:41am, Thursday, 23'rd Jul 2026
Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Wednesday, 22'nd Jul 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026.
These major drug stocks rally after Trump's zero tariff announcement
06:31am, Wednesday, 22'nd Jul 2026
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
07:57am, Tuesday, 21'st Jul 2026
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
08:18pm, Monday, 20'th Jul 2026
The transaction involved 40,000 shares with an estimated value of $3.5 million on the July 15, 2026 transaction date. The activity was executed through the conversion of 40,000 options at $19.26 and $
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
08:08pm, Monday, 20'th Jul 2026
The transaction involved the sale of 10,000 shares at $88.30 per share, resulting in a total value of $883,000 on July 15, 2026. The sale reduced the insider's total indirect equity holdings by 0.67%.
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
03:06pm, Sunday, 12'th Jul 2026
The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors
12:06pm, Friday, 10'th Jul 2026
Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval i
